BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38262977)

  • 21. Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases.
    Wang Y; Wu S; Li J; Liang X; Zhou X
    Brain Sci; 2023 Sep; 13(9):. PubMed ID: 37759881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer.
    Wandrey NE; Gao D; Robin TP; Contessa JN; Singh C; Chiang V; Li J; Chen A; Wang Y; Sheehan JP; Dutta SW; Weiss SE; Paly J; Rusthoven CG
    Lung Cancer; 2023 Feb; 176():144-148. PubMed ID: 36641932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.
    Du XJ; Pan SM; Lai SZ; Xu XN; Deng ML; Wang XH; Yao DC; Wu SX
    Front Oncol; 2018; 8():603. PubMed ID: 30619745
    [No Abstract]   [Full Text] [Related]  

  • 24. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
    Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.
    Wang W; Song Z; Zhang Y
    Arch Med Sci; 2018 Oct; 14(6):1298-1307. PubMed ID: 30393484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases.
    Dong K; Liang W; Zhao S; Guo M; He Q; Li C; Song H; He J; Xia X
    Transl Lung Cancer Res; 2019 Jun; 8(3):268-279. PubMed ID: 31367540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.
    Thomas NJ; Myall NJ; Sun F; Patil T; Mushtaq R; Yu C; Sinha S; Pollom EL; Nagpal S; Camidge DR; Rusthoven CG; Braunstein SE; Wakelee HA; McCoach CE
    J Thorac Oncol; 2022 Jan; 17(1):116-129. PubMed ID: 34455066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
    Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
    Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study.
    Liu Y; Wang J; Wu J; Yang Q; Zeng Y; Wu D; Tian C; Hu Y; Gu F; Li C; Zhang K; Liu L
    Technol Cancer Res Treat; 2021; 20():1533033821997819. PubMed ID: 33715525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.
    El Shafie RA; Seidensaal K; Bozorgmehr F; Kazdal D; Eichkorn T; Elshiaty M; Weber D; Allgäuer M; König L; Lang K; Forster T; Arians N; Rieken S; Heussel CP; Herth FJ; Thomas M; Stenzinger A; Debus J; Christopoulos P
    ESMO Open; 2021 Jun; 6(3):100161. PubMed ID: 34090172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F; Cheng X; Zeng H; Miao J; Hou M
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of whole-brain radiotherapy with platinum-based chemotherapy in non-small cell lung cancer patients with multiple metastases including brain metastases.
    Ryu WK; Cha HK; Kim W; Lee HY; Kim HJ; Ryu JS; Lim JH
    Sci Rep; 2023 Aug; 13(1):13173. PubMed ID: 37580499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
    Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.